- Drugmaker Glenmark has entered into an exclusive marketing and distribution agreement with BeiGene to register and commercialise the latter’s oncology medicines Tislelizumab and Zanubrutinib in India.
- Glenmark will be responsible for locally required development, registration and distribution providing access to BeiGene’s oncology medicines for cancer patients across India.
- Tislelizumab is a novel anti-programmed cell death protein 1 (PD-1) monoclonal antibody for the treatment of advanced or metastatic oesophagus squamous cell carcinoma and broad development for the treatment of various types of cancers.
- Zanubrutinib is a BTK inhibitor approved for the treatment of certain haematological malignancies, with results of studies reinforcing favourable efficacy and safety profile.
Dig Deeper: Read about the recent breakthroughs in the fight against Cancer.
